Brief: SpringWorks Therapeutics Initiates Rolling Submission of New Drug Application to the FDA
04/03/2024 11:33
March 4 (Reuters) - SpringWorks Therapeutics Inc
SWTX.O :
* SPRINGWORKS THERAPEUTICS INITIATES ROLLING SUBMISSION OF
NEW
DRUG APPLICATION TO THE FDA FOR MIRDAMETINIB FOR THE TREATMENT
OF CHILDREN AND ADULTS WITH NF1-PN
* SPRINGWORKS THERAPEUTICS INC - EXPECTS TO COMPLETE NDA
SUBMISSION IN Q2 OF 2024
Source text for Eikon: ID:nGNXgFnPw
Further company coverage: SWTX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on SpringWorks Therapeutics
See all newsBrief: Merck KGaA Completes Acquisition Of Springworks Therapeutics
Brief: Springworks Therapeutics Expects Nirogacestat Decision From European Commission In Q3
Brief: EMA's CHMP Re-Examines Rejection Of Kisunla For Early Alzheimer’S Treatment
Brief: SpringWorks Therapeutics Receives Positive CHMP Opinion for Mirdametinib for the Treatment of Adult and Pediatric Patients with NF1-PN
Brief: SpringWorks Therapeutics Receives Positive CHMP Opinion For Mirdametinib For The Treatment Of Adult And Pediatric Patients With NF1-PN